Table 3

Previous studies of partial (0.6 mg/kg) versus full-dose (0.9 mg/kg) intravenous rt-PA followed by endovascular therapy

Author, year	Demographics				Endpoints
Author, year	N	Age in years, median (range) or mean±SD	Sex, men (%)	NIHSS, median (IQR or range) or mean±SD	Revascularization rate (TIMI/TICI 2–3) (%)	Favorable outcome (%)	sICH (%)	Mortality (%)
0.6 mg/kg intravenous rt-PA
EMS, 19991	17	66±11	53	16 (IQR 9–21)	82	33^*	11.8	29
Ernst et al, 20002	20	69 (36–89)	45	21 (range 11–31)	69	65^†	5	10
IMS, 20043	62	64±13^¶	50^¶	18±5^¶	56	24.2^*	6.3^¶	16^¶
Flaherty et al, 20054	62	69 (20-89)	40	18 (range 11–34)	59	50^†	8	18
IMS II, 20075	55	64±11^**	57^**	19±5^**	60	33^† ^**	10^**	16^**
Wolfe et al, 20086	41	67±14	39	17 (IQR 11–20)	66	46^†	12	27
Sugiura et al, 20087	16	70±9	69	19±2	88	63^*	0	6
0.9 mg/kg intravenous rt-PA
Hill et al, 20028	8	57±18	88	18 (range 10–24)	38	38^†	0	12
Lee et al, 20049	16	63±8	37	19±5	75	69^†	6.2	6.2
Shaltoni et al, 200710	69	60±13	55	18 (range 6–39)	73	55^‡	6	17.4
Smith et al, 200811	48	68±16^††	43^††	19 (IQR 15–23)^††	73	38^†	10, 2.1^§§	28
Burns et al, 200812	33	67±12	33	16±3	73^‡‡	33.3^†	12	12.1
Nogueira et al, 2011	106	69±17	45	18±5	66	24^† 44^§	8.5	32.4

↵* 90-day modified Rankin Scale (mRS) ≤1.
↵† 90-day mRS ≤2.
↵‡ Discharged to home/rehabilitation.
↵§ Ambulatory at discharge.
↵¶ Overall IMS trial cohort (n=80).
↵** Overall IMS II trial cohort (n=81).
↵†† Overall Multi Merci trial cohort (n=164).
↵‡‡ ≥1 Improvement in Qureshi grade.
↵§§ Symptomatic parenchymal hematoma type 2.
NIHSS, NIH Stroke Scale; rt-PA, recombinant tissue plasminogen activator; sICH, symptomatic intracranial hemorrhage; TICI, Thrombolysis in Cerebral Infarction; TIMI, Thrombolysis in Myocardial Infarction.